See more : GPS Alliance Holdings Limited (GPS.AX) Income Statement Analysis – Financial Results
Complete financial analysis of NanoVibronix, Inc. (NAOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoVibronix, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Noevir Holdings Co., Ltd. (4928.T) Income Statement Analysis – Financial Results
- Taiwan Numerical Powers Co., Ltd. (6593.TWO) Income Statement Analysis – Financial Results
- Donglai Coating Technology (Shanghai) Co., Ltd. (688129.SS) Income Statement Analysis – Financial Results
- 91App, Inc. (6741.TWO) Income Statement Analysis – Financial Results
- C&C Group plc (CCGPY) Income Statement Analysis – Financial Results
NanoVibronix, Inc. (NAOV)
About NanoVibronix, Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.28M | 752.00K | 1.70M | 623.00K | 530.00K | 318.00K | 239.00K | 229.00K | 147.00K | 203.00K | 211.00K | 166.00K | 94.00K |
| Cost of Revenue | 746.00K | 585.00K | 925.00K | 409.00K | 249.00K | 158.00K | 88.00K | 88.00K | 49.00K | 93.00K | 91.00K | 50.00K | 29.00K |
| Gross Profit | 1.54M | 167.00K | 770.00K | 214.00K | 281.00K | 160.00K | 151.00K | 141.00K | 98.00K | 110.00K | 120.00K | 116.00K | 65.00K |
| Gross Profit Ratio | 67.32% | 22.21% | 45.43% | 34.35% | 53.02% | 50.31% | 63.18% | 61.57% | 66.67% | 54.19% | 56.87% | 69.88% | 69.15% |
| Research & Development | 185.00K | 283.00K | 293.00K | 171.00K | 514.00K | 614.00K | 693.00K | 584.00K | 399.00K | 431.00K | 620.00K | 572.00K | 510.00K |
| General & Administrative | 3.92M | 3.93M | 5.06M | 3.77M | 3.82M | 2.64M | 2.08M | 1.36M | 747.00K | 589.00K | 366.00K | 128.00K | 87.00K |
| Selling & Marketing | 864.00K | 965.00K | 1.10M | 993.00K | 1.10M | 1.21M | 465.00K | 514.00K | 377.00K | 301.00K | 244.00K | 190.00K | 150.00K |
| SG&A | 4.79M | 4.90M | 6.16M | 4.76M | 4.92M | 3.85M | 2.55M | 1.87M | 1.12M | 890.00K | 610.00K | 318.00K | 237.00K |
| Other Expenses | 0.00 | 0.00 | -1.63M | 42.00K | -412.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 0.00 | 0.00 |
| Operating Expenses | 4.97M | 5.18M | 6.45M | 4.93M | 5.43M | 4.46M | 3.24M | 2.46M | 1.52M | 1.32M | 1.23M | 890.00K | 747.00K |
| Cost & Expenses | 5.72M | 5.76M | 7.38M | 5.34M | 5.68M | 4.62M | 3.33M | 2.55M | 1.57M | 1.41M | 1.32M | 940.00K | 776.00K |
| Interest Income | 0.00 | 54.00K | 48.00K | 147.00K | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 1.00K | 1.00K |
| Interest Expense | 246.00K | 347.00K | 0.00 | 147.00K | 62.00K | 22.00K | 1.23M | 0.00 | 65.00K | 372.00K | 782.00K | 256.00K | 21.00K |
| Depreciation & Amortization | 1.00K | 1.00K | 2.00K | 2.00K | 4.00K | 6.00K | 5.00K | 7.00K | 9.00K | 9.00K | 10.00K | 9.00K | 10.00K |
| EBITDA | -3.44M | -5.01M | -14.25M | -4.16M | -5.75M | -4.28M | -3.64M | -2.69M | -2.38M | -1.33M | -1.23M | -1.01M | -692.00K |
| EBITDA Ratio | -150.46% | -673.54% | -433.98% | -757.14% | -1,048.87% | -1,344.34% | -1,313.39% | -1,014.85% | -1,238.10% | -1,024.14% | -771.56% | -608.43% | -736.17% |
| Operating Income | -3.44M | -5.01M | -5.68M | -4.72M | -5.15M | -4.30M | -3.09M | -2.32M | -1.42M | -1.21M | -1.11M | -774.00K | -682.00K |
| Operating Income Ratio | -150.50% | -666.49% | -335.28% | -757.46% | -971.89% | -1,353.14% | -1,293.31% | -1,011.35% | -968.71% | -596.55% | -526.07% | -466.27% | -725.53% |
| Total Other Income/Expenses | -246.00K | -401.00K | -8.57M | 408.00K | -660.00K | 22.00K | -1.84M | -398.00K | -1.43M | -1.39M | -844.00K | -501.00K | -41.00K |
| Income Before Tax | -3.68M | -5.41M | -14.25M | -4.31M | -5.81M | -4.28M | -4.93M | -2.71M | -2.86M | -2.60M | -1.95M | -1.28M | -723.00K |
| Income Before Tax Ratio | -161.28% | -719.81% | -840.71% | -691.97% | -1,096.42% | -1,346.23% | -2,061.51% | -1,185.15% | -1,942.86% | -1,279.80% | -926.07% | -768.07% | -769.15% |
| Income Tax Expense | 29.00K | 35.00K | 32.00K | 15.00K | -17.00K | -127.00K | 38.00K | 117.00K | 28.00K | 49.00K | 35.00K | 10.00K | -20.00K |
| Net Income | -3.71M | -5.45M | -14.28M | -4.33M | -5.79M | -4.15M | -4.97M | -2.83M | -2.88M | -2.65M | -1.99M | -1.28M | -723.00K |
| Net Income Ratio | -162.55% | -724.47% | -842.60% | -694.38% | -1,093.21% | -1,306.29% | -2,077.41% | -1,236.24% | -1,961.90% | -1,303.94% | -942.65% | -768.07% | -769.15% |
| EPS | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| EPS Diluted | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| Weighted Avg Shares Out | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
| Weighted Avg Shares Out (Dil) | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
NanoVibronix Advances Efforts to Achieve NHS Approval
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has received the publication of Guidance from the National Institute for Health...
Best Penny Stocks to Buy Now? Here's 3 to Watch in April 2022
Can these penny stocks continue to make moves next month? The post Best Penny Stocks to Buy Now?
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA...
Health Canada Approves NanoVibronix's PainGuard, UroGuard As Licensed Devices
NanoVibronix Inc's (NASDAQ: NAOV) PainGuard and UroGuard have been approved by Health Canada / Santé Canada as licensed medical devices. The products are offered as private label products through Ideal Medical International Limited.
NanoVibronix Announces PainGuard and UroGuard Approved by Health Canada as Licensed Medical Devices
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced the Company’s PainGuard and UroGuard, offered as private label products through Ideal Medical International...
NanoVibronix Announces PainGuard and UroGuard Approved by Health Canada as Licensed Medical Devices
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced the Company's PainGuard and UroGuard, offered as private label products through Ideal Medical International...
NanoVibronix Added an Additional National Payer Network in Workers' Compensation Market
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a Provider Agreement with EZ Health Care. Under the terms of...
NanoVibronix Added an Additional National Payer Network in Workers’ Compensation Market
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a Provider Agreement with EZ Health Care. Under the terms of...
NanoVibronix Extends Reach of UroShield and PainShield through MTSG’s International Network
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed an International Marketing, Sales and Clinical Management Agreement with Medtech Solutions...
NanoVibronix Extends Reach of UroShield and PainShield through MTSG's International Network
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed an International Marketing, Sales and Clinical Management Agreement with Medtech Solutions...
Source: https://incomestatements.info
Category: Stock Reports